Tamsoli Dosage/Direction for Use

Adult males, including older people: One Tamsoli tablet (0.4 mg/6 mg) once daily taken orally with or without food. The maximum daily dose is one Tamsoli tablet (0.4 mg/6 mg).
The tablet must be swallowed whole, intact without biting or chewing. Do not crush the tablet.
Patients with renal impairment: The effect of renal impairment on the pharmacokinetics of combination of tamsulosin and solifenacin has not been studied. However, the effect on the pharmacokinetics of the individual active substances is well known. Tamsoli can be used in patients with mild to moderate renal impairment (creatinine clearance >30 mL/min). Patients with severe renal impairment (creatinine clearance ≤30 mL/min) should be treated with caution and the maximum daily dose in these patients is one Tamsoli tablet (0.4 mg/6 mg).
Patients with hepatic impairment: The effect of hepatic impairment on the pharmacokinetics of combination of tamsulosin and solifenacin has not been studied. However, the effect on the pharmacokinetics of the individual active substances is well known. Tamsoli can be used in patients with mild hepatic impairment (Child-Pugh score ≤7). Patients with moderate hepatic impairment (Child-Pugh score 7-9) should be treated with caution and the maximum daily dose in these patients is one Tamsoli tablet (0.4 mg/6 mg). In patients with severe hepatic impairment (Child-Pugh score >9), the use of Tamsoli is contraindicated.
Moderate and strong inhibitors of cytochrome P450 3A4: The maximum daily dose of Tamsoli should be limited to one tablet (0.4 mg/6 mg). Tamsoli should be used with caution in patients treated simultaneously with moderate or strong CYP3A4 inhibitors, e.g. verapamil, ketoconazole, ritonavir, nelfinavir, itraconazole.
Paediatric population: There is no relevant indication for use of Tamsoli in children and adolescents.